Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07003425 · ClinicalTrials.gov registry record · Phase 2
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Apogee Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT07003425: Recruiting Phase 2 study of Atopic Dermatitis, sponsored by Apogee Therapeutics.
NCT07003425 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Apogee Therapeutics. The registered enrollment target is 350 participants, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07003425, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Apogee Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period. This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.
Conditions Studied
Interventions
- DRUG APG777
Study Locations (20)
Florida
- Investigational Site - Coral Gables
- Investigational Site - Jacksonville
- Investigational Site - Margate
Texas
- Investigational Site - Dallas
- Investigational Site - Frisco
- Investigational Site - San Antonio
California
- Investigational Site - Fountain Valley
- Investigational Site - Los Angeles
Michigan
- Investigational Site - Detroit
- Investigational Site - Troy
Ohio
- Investigational Site - Boardman
- Investigational Site - Mason
Georgia
- Investigational Site - Douglasville
Illinois
- Investigational Site - Skokie
Kentucky
- Investigational Site - Bowling Green
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2025-05-14 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
What NCT07003425 shows while recruiting
NCT07003425 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which APG777 is the first listed.
NCT07003425 names 20 study sites across 13 states, led by Florida, Texas, California.
Frequently Asked Questions
What is clinical trial NCT07003425 about?
NCT07003425 is a clinical study titled "A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis". This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will ...
What is the current status of trial NCT07003425?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2025-05-14. Estimated completion is 2029-12.
What conditions does trial NCT07003425 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT07003425?
The interventions under investigation include: APG777 (DRUG).
Who is sponsoring clinical trial NCT07003425?
This trial is sponsored by Apogee Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07003425 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07003425's enrollment target sits among peer trials
350 38th of 150 higher than 113 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI